Literature DB >> 27135430

[Bone Conduction and Active Middle Ear Implants].

S Volkenstein1, J P Thomas1, S Dazert1.   

Abstract

The majority of patients with moderate to severe hearing loss can be supplied with conventional hearing aids depending on severity and cause for hearing loss in a satisfying way. However, some patients either do not benefit enough from conventional hearing aids or cannot wear them due to inflammatory reactions and chronic infections of the external auditory canal or due to anatomical reasons. For these patients there are fully- and semi-implantable middle ear and bone conduction implants available. These devices either directly stimulate the skull (bone conduction devices), middle ear structures (active middle ear implants) or the cochlea itself (direct acoustic stimulation). Patients who failed surgical hearing rehabilitation or do not benefit from conventional hearing aids may achieve a significant better speech understanding and tremendous improvement in quality of life by implantable hearing devices with careful attention to the audiological and anatomical indication criteria. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27135430     DOI: 10.1055/s-0042-104946

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  3 in total

Review 1.  Hearing Impairment in Old Age.

Authors:  Jan Löhler; Mario Cebulla; Wafaa Shehata-Dieler; Stefan Volkenstein; Christiane Völter; Leif Erik Walther
Journal:  Dtsch Arztebl Int       Date:  2019-04-26       Impact factor: 5.594

2.  Vibrant Soundbridge® in preschool children with unilateral aural atresia: acceptance and benefit.

Authors:  M Leinung; E Zaretsky; B P Lange; V Hoffmann; T Stöver; C Hey
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-25       Impact factor: 2.503

3.  Mapping the ChOLE classification to hearing outcomes and disease-specific health-related quality of life.

Authors:  Nora M Weiss; David Bächinger; Adrian Rrahmani; Hans E Bernd; Alexander Huber; Robert Mlynski; Christof Röösli
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-05-05       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.